Review Article | Published:

Cannabinoids for the treatment of rheumatic diseases — where do we stand?

Nature Reviews Rheumatologyvolume 14pages488498 (2018) | Download Citation


As medical use of cannabis is increasingly legalized worldwide, a better understanding of the medical and hazardous effects of this drug is imperative. The pain associated with rheumatic diseases is considered a prevalent indication for medicinal cannabis in various countries. Thus far, preliminary clinical trials have explored the effects of cannabis on rheumatoid arthritis, osteoarthritis and fibromyalgia; preliminary evidence has also found an association between the cannabinoid system and other rheumatic conditions, including systemic sclerosis and juvenile idiopathic arthritis. The potential medicinal effects of cannabis could be attributable to its influence on the immune system, as it exerts an immunomodulatory effect on various immune cells, including T cells, B cells and macrophages. However, the available evidence is not yet sufficient to support the recommendation of cannabinoid treatment for rheumatic diseases.

Key points

  • Cannabinoids can affect the proliferation, apoptosis and cytokine production of immune cells, acting as possible immune modulators.

  • Preclinical data suggest that cannabinoids possess therapeutic potential in the following rheumatic diseases: rheumatoid arthritis, osteoarthritis, systemic sclerosis and fibromyalgia.

  • Clinical data regarding cannabinoid treatment for rheumatic diseases are scarce; therefore, recommendations concerning cannabinoid treatment cannot be made.

  • Cannabinoid treatment should not be taken lightly; special consideration and advise are required regarding adverse effects and drug interactions.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Warf, B. High points: an historical geography of cannabis. Geogr. Rev. 104, 414–438 (2014).

  2. 2.

    Zuardi, A. W. History of cannabis as a medicine: a review. Revista Brasileira Psiquiatria 28, 153–157 (2006).

  3. 3.

    Pain, S. A potted history. Nature 525, S10–S11 (2015).

  4. 4.

    Katchan, V., David, P. & Shoenfeld, Y. Cannabinoids and autoimmune diseases: a systematic review. Autoimmun. Rev. 15, 513–528 (2016).

  5. 5.

    Gaoni, Y. & Mechoulam, R. Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86, 1646–1647 (1964).

  6. 6.

    Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S. & Howlett, A. C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34, 605–613 (1988).

  7. 7.

    Devane, W. A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946–1949 (1992).

  8. 8.

    Mechoulam, R. et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83–90 (1995).

  9. 9.

    Maccarrone, M. et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol. Sci. 36, 277–296 (2015).

  10. 10.

    Mechoulam, R. Cannabis - the Israeli perspective. J. Basic Clin. Physiol. Pharmacol. 27, 181–187 (2016).

  11. 11.

    Iversen, L. Cannabis and the brain. Brain 126, 1252–1270 (2003).

  12. 12.

    Mackie, K. Mechanisms of CB1 receptor signaling: endocannabinoid modulation of synaptic strength. Int. J. Obes. 30 (Suppl. 1), S19–S23 (2006).

  13. 13.

    Pagotto, U., Marsicano, G., Cota, D., Lutz, B. & Pasquali, R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr. Rev. 27, 73–100 (2006).

  14. 14.

    Guindon, J. & Hohmann, A. G. The endocannabinoid system and pain. CNS Neurol. Disord. Drug Targets 8, 403–421 (2009).

  15. 15.

    Sido, J. M., Nagarkatti, P. S. & Nagarkatti, M. Role of endocannabinoid activation of peripheral CB1 receptors in the regulation of autoimmune disease. Int. Rev. Immunol. 34, 403–414 (2015).

  16. 16.

    Dunn, S. L., Wilkinson, J. M., Crawford, A., Bunning, R. A. D. & Le Maitre, C. L. Expression of cannabinoid receptors in human osteoarthritic cartilage: implications for future therapies. Cannabis Cannabinoid Res. 1, 3–15 (2016).

  17. 17.

    Castillo, P. E., Younts, T. J., Chávez, A. E. & Hashimotodani, Y. Endocannabinoid signaling and synaptic function. Neuron 76, 70–81 (2012).

  18. 18.

    Howlett, A. C. et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54, 161–202 (2002).

  19. 19.

    Howlett, A. C., Blume, L. C. & Dalton, G. D. CB1 cannabinoid receptors and their associated proteins. Curr. Med. Chem. 17, 1382–1393 (2010).

  20. 20.

    Pertwee, R. G. et al. International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol. Rev. 62, 588–631 (2010).

  21. 21.

    Aghazadeh Tabrizi, M., Baraldi, P. G., Borea, P. A. & Varani, K. Medicinal chemistry, pharmacology, and potential therapeutic benefits of cannabinoid CB 2 receptor agonists. Chem. Rev. 116, 519–560 (2016).

  22. 22.

    Gui, H. et al. Expression of cannabinoid receptor 2 and its inhibitory effects on synovial fibroblasts in rheumatoid arthritis. Rheumatology 53, 802–809 (2014).

  23. 23.

    Malfitano, A. M., Basu, S., Maresz, K., Bifulco, M. & Dittel, B. N. What we know and do not know about the cannabinoid receptor 2 (CB2). Semin. Immunol. 26, 369–379 (2014).

  24. 24.

    Beltramo, M. et al. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur. J. Neurosci. 23, 1530–1538 (2006).

  25. 25.

    Katz, D., Katz, I., Porat-Katz, B. & Shoenfeld, Y. Medical cannabis: another piece in the mosaic of autoimmunity? Clin. Pharmacol. Ther. 101, 230–238 (2016).

  26. 26.

    Bellini, G. et al. Association between cannabinoid receptor type 2 Q63R variant and oligo/polyarticular juvenile idiopathic arthritis. Scand. J. Rheumatol. 44, 284–287 (2015).

  27. 27.

    Engler, A. et al. Expression of transient receptor potential vanilloid 1 (TRPV1) in synovial fibroblasts from patients with osteoarthritis and rheumatoid arthritis. Biochem. Biophys. Res. Commun. 359, 884–888 (2007).

  28. 28.

    Barrie, N. et al. Endocannabinoids in arthritis: current views and perspective. Int. J. Rheum. Dis. 20, 789–797 (2017).

  29. 29.

    Lowin, T. & Straub, R. H. Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis. Arthritis Res. Ther. 17, 226 (2015).

  30. 30.

    Irving, A. et al. Cannabinoid receptor-related orphan G protein-coupled receptors. Adv. Pharmacol. 80, 223–247 (2017).

  31. 31.

    Katz, D., Katz, I. & Shoenfeld, Y. Cannabis and autoimmunity–the neurologic perspective: a brief review. J. Neurol. Neuromed. 1, 11–15 (2016).

  32. 32.

    Pertwee, R. G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74, 129–180 (1997).

  33. 33.

    Thomas, A. et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol. 150, 613–623 (2007).

  34. 34.

    Ligresti, A., De Petrocellis, L. & Di Marzo, V. From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiol. Rev. 96, 1593–1659 (2016).

  35. 35.

    Ben-Shabat, S. et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 353, 23–31 (1998).

  36. 36.

    Russo, E. B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br. J. Pharmacol. 163, 1344–1364 (2011).

  37. 37.

    Russo, E. B. & Marcu, J. Cannabis pharmacology: the usual suspects and a few promising leads. Adv. Pharmacol. 80, 67–134 (2017).

  38. 38.

    Jiang, C.-P. et al. Anti-rheumatoid arthritic activity of flavonoids from Daphne genkwa. Phytomedicine 21, 830–837 (2014).

  39. 39.

    Parmar, J. R., Forrest, B. D. & Freeman, R. A. Medical marijuana patient counseling points for health care professionals based on trends in the medical uses, efficacy, and adverse effects of cannabis-based pharmaceutical drugs. Res. Soc. Adm. Pharm. 12, 638–654 (2016).

  40. 40.

    Adams, A. J. et al. ‘Zombie’ outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. N. Engl. J. Med. 376, 235–242 (2017).

  41. 41.

    Wang, T., Collet, J.-P., Shapiro, S. & Ware, M. A. Adverse effects of medical cannabinoids: a systematic review. CMAJ 178, 1669–1678 (2008).

  42. 42.

    Tait, R. J., Caldicott, D., Mountain, D., Hill, S. L. & Lenton, S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin. Toxicol. 54, 1–13 (2015).

  43. 43.

    National Academies of Sciences, Engineering and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research (The National Academies Press, 2017).

  44. 44.

    Auer, R. et al. Association between lifetime marijuana use and cognitive function in middle age. JAMA Intern. Med. 176, 352 (2016).

  45. 45.

    Batalla, A. et al. Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS ONE 8, e55821 (2013).

  46. 46.

    Rocchetti, M. et al. Is cannabis neurotoxic for the healthy brain? A meta-analytical review of structural brain alterations in non-psychotic users. Psychiatry Clin. Neurosci. 67, 483–492 (2013).

  47. 47.

    Meier, M. H. et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc. Natl Acad. Sci. USA 109, E2657–E2664 (2012).

  48. 48.

    Volkow, N. D., Baler, R. D., Compton, W. M. & Weiss, S. R. B. Adverse health effects of marijuana use. N. Engl. J. Med. 370, 2219–2227 (2014).

  49. 49.

    Curran, H. V. et al. Keep off the grass? Cannabis, cognition and addiction. Nat. Rev. Neurosci. 17, 293–306 (2016).

  50. 50.

    Meier, M. H. et al. Associations between adolescent cannabis use and neuropsychological decline: a longitudinal co-twin control study. Addiction 113, 257–265 (2017).

  51. 51.

    Anthony, J. C., Warner, L.a. & Kessler, R. C. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp. Clin. Psychopharmacol. 2, 244–268 (1994).

  52. 52.

    Agrawal, A. & Lynskey, M. T. Candidate genes for cannabis use disorders: findings, challenges and directions. Addiction 104, 518–532 (2009).

  53. 53.

    Verweij, K. J. H. et al. Genetic and environmental influences on cannabis use initiation and problematic use: a meta-analysis of twin studies. Addiction 105, 417–430 (2010).

  54. 54.

    Smith, A. M. et al. Prenatal marijuana exposure impacts executive functioning into young adulthood: an fMRI study. Neurotoxicol. Teratol. 58, 53–59 (2016).

  55. 55.

    Kerbrat, A. et al. Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase. N. Engl. J. Med. 375, 1717–1725 (2016).

  56. 56.

    Lindsey, W. T., Stewart, D. & Childress, D. Drug interactions between common illicit drugs and prescription therapies. Am. J. Drug Alcohol Abuse 38, 334–343 (2012).

  57. 57.

    Stout, S. M. & Cimino, N. M. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab. Rev. 46, 86–95 (2014).

  58. 58.

    Anderson, G. D. & Chan, L. N. Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products. Clin. Pharmacokinet. 55, 1353–1368 (2016).

  59. 59.

    Geffrey, A. L., Pollack, S. F., Bruno, P. L. & Thiele, E. A. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 56, 1246–1251 (2015).

  60. 60.

    Abrams, D. I., Couey, P., Shade, S. B., Kelly, M. E. & Benowitz, N. L. Cannabinoid–opioid interaction in chronic pain. Clin. Pharmacol. Ther. 90, 844–851 (2011).

  61. 61.

    Hartman, R. L. et al. Controlled cannabis vaporizer administration: blood and plasma cannabinoids with and without alcohol. Clin. Chem. 61, 850–869 (2015).

  62. 62.

    McLeod, A. L., McKenna, C. J. & Northridge, D. B. Myocardial infarction following the combined recreational use of Viagra and cannabis. Clin. Cardiol. 25, 133–134 (2002).

  63. 63.

    Yamreudeewong, W., Wong, H. K., Brausch, L. M. & Pulley, K. R. Probable interaction between warfarin and marijuana smoking. Ann. Pharmacother. 43, 1347–1353 (2009).

  64. 64.

    Shapira, Y., Agmon-Levin, N. & Shoenfeld, Y. Geoepidemiology of autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 6, 468–476 (2010).

  65. 65.

    Richardson, D. et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res. Ther. 10, R43 (2008).

  66. 66.

    Lowin, T., Pongratz, G. & Straub, R. H. The synthetic cannabinoid WIN55,212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB2, TRPV1, TRPA1 and yet unidentified receptor targets. J. Inflamm. 13, 15 (2016).

  67. 67.

    Malfait, A. M. et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl Acad. Sci. USA 97, 9561–9566 (2000).

  68. 68.

    Fukuda, S. et al. Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis. BMC Musculoskelet. Disord. 15, 275 (2014).

  69. 69.

    Gui, H., Liu, X., Liu, L.-R., Su, D.-F. & Dai, S.-M. Activation of cannabinoid receptor 2 attenuates synovitis and joint distruction in collagen-induced arthritis. Immunobiology 220, 817–822 (2015).

  70. 70.

    Blake, D. R., Robson, P., Ho, M., Jubb, R. W. & McCabe, C. S. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 45, 50–52 (2006).

  71. 71.

    Kong, Y. et al. Cannabinoid WIN-55,212–2 mesylate inhibits ADAMTS-4 activity in human osteoarthritic articular chondrocytes by inhibiting expression of syndecan-1. Mol. Med. Rep. 13, 4569–4576 (2016).

  72. 72.

    Ste-Marie, P. A. et al. Survey of herbal cannabis (marijuana) use in rheumatology clinic attenders with a rheumatologist confirmed diagnosis. Pain 157, 2792–2797 (2016).

  73. 73.

    Bannuru, R. R. et al. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis. Ann. Intern. Med. 162, 46 (2015).

  74. 74.

    Sophocleous, A., Börjesson, A. E., Salter, D. M. & Ralston, S. H. The type 2 cannabinoid receptor regulates susceptibility to osteoarthritis in mice. Osteoarthritis Cartilage 23, 1586–1594 (2015).

  75. 75.

    Mbvundula, E. C., Bunning, R. A. D. & Rainsford, K. D. Effects of cannabinoids on nitric oxide production by chondrocytes and proteoglycan degradation in cartilage. Biochem. Pharmacol. 69, 635–640 (2005).

  76. 76.

    Gõmez, R. et al. Endogenous cannabinoid anandamide impairs cell growth and induces apoptosis in chondrocytes. J. Orthop. Res. 32, 1137–1146 (2014).

  77. 77.

    Huggins, J. P., Smart, T. S., Langman, S., Taylor, L. & Young, T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 153, 1837–1846 (2012).

  78. 78.

    La Porta, C. et al. Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain. Pain 156, 2001–2012 (2015).

  79. 79.

    Schuelert, N. et al. Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis. Pain 152, 975–981 (2011).

  80. 80.

    Rossi, D. et al. How I treat patients with systemic sclerosis in clinical practice. Autoimmun. Rev. 16, 1024–1028 (2017).

  81. 81.

    Marquart, S. et al. Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis Rheum. 62, 3467–3476 (2010).

  82. 82.

    Akhmetshina, A. et al. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum. 60, 1129–1136 (2009).

  83. 83.

    del Río, C. et al. The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways. Sci. Rep. 6, 21703 (2016).

  84. 84.

    Servettaz, A. et al. Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. Am. J. Pathol. 177, 187–196 (2010).

  85. 85.

    Wang, L.-L. et al. Pharmacological activation of cannabinoid 2 receptor attenuates inflammation, fibrogenesis, and promotes re-epithelialization during skin wound healing. Eur. J. Pharmacol. 786, 128–136 (2016).

  86. 86.

    Li, S. et al. Cannabinoid CB2 receptors are involved in the regulation of fibrogenesis during skin wound repair in mice. Mol. Med. Rep. 13, 3441–3450 (2016).

  87. 87.

    Garcia-Gonzalez, E. et al. Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts. Rheumatology 48, 1050–1056 (2009).

  88. 88.

    Wolfe, F. et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin. Arthritis Rheum. 46, 319–329 (2016).

  89. 89.

    Fitzcharles, M.-A. & Jamal, S. Expanding medical marijuana access in Canada: considerations for the rheumatologist. J. Rheumatol. 42, 143–145 (2015).

  90. 90.

    Walsh, Z. et al. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int. J. Drug Policy 24, 511–516 (2013).

  91. 91.

    Ware, M. A., Adams, H., Guy, G. W. & Centre, P. The medicinal use of cannabis in the UK: results of a nationwide survey. Int. J. Clin. Pract. 59, 291–295 (2005).

  92. 92.

    Aggarwal, S. K. et al. Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. J. Opioid Manag. 5, 257–286 (2009).

  93. 93.

    Walitt, B., Klose, P., Fitzcharles, M. A., Phillips, T. & Häuser, W. Cannabinoids for fibromyalgia. Cochrane Database Syst. Rev. 7, CD011694 (2016).

  94. 94.

    Skrabek, R. Q., Galimova, L., Ethans, K. & Perry, D. Nabilone for the treatment of pain in fibromyalgia. J. Pain 9, 164–173 (2008).

  95. 95.

    Ware, M. A., Fitzcharles, M.-A., Joseph, L. & Shir, Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth. Analg. 110, 604–610 (2010).

  96. 96.

    Fiz, J., Durán, M., Capellà, D., Carbonell, J. & Farré, M. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS ONE 6, e18440 (2011).

  97. 97.

    Fitzcharles, M.-A. et al. Rheumatologists lack confidence in their knowledge of cannabinoids pertaining to the management of rheumatic complaints. BMC Musculoskelet. Disord. 15, 258 (2014).

  98. 98.

    Robinson, R. H. et al. A CB2-selective cannabinoid suppresses T-cell activities and increases Tregs and IL-10. J. Neuroimmune Pharmacol. 10, 318–332 (2015).

  99. 99.

    Gonzalez, E. G. et al. Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis. Ann. Rheum. Dis. 71, 1545–1551 (2012).

  100. 100.

    Whiting, P. F. et al. Cannabinoids for medical use. JAMA 313, 2456 (2015).

  101. 101.

    Fitzcharles, M.-A., Baerwald, C., Ablin, J. & Häuser, W. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): a systematic review of randomized controlled trials. Schmerz 30, 47–61 (2016).

  102. 102.

    Katz, I., Katz, D., Shoenfeld, Y. & Porat-Katz, B. S. Clinical evidence for utilizing cannabinoids in the elderly. Isr. Med. Assoc. J. 19, 71–75 (2017).

  103. 103.

    Gunn, J. K. L. et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open 6, e009986 (2016).

  104. 104.

    Hall, W. & Degenhardt, L. The adverse health effects of chronic cannabis use. Drug Test. Anal. 6, 39–45 (2014).

  105. 105.

    Schrot, R. J. & Hubbard, J. R. Cannabinoids: medical implications. Ann. Med. 48, 128–141 (2016).

  106. 106.

    Silins, E. et al. Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiatry 1, 286–293 (2014).

  107. 107.

    Solowij, N. Adolescent cannabis use: what is the evidence for functional brain alteration? Curr. Pharm. Des. 22, 6353–6365 (2016).

  108. 108.

    Chabarria, K. C. et al. Marijuana use and its effects in pregnancy. Am. J. Obstet Gynecol. 215, 506.e1–506.e7 (2016).

  109. 109.

    Vaucher, J. et al. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Mol. Psychiatry 23, 1287–1292 (2017).

  110. 110.

    Mittleman, M. A., Lewis, R. A., Maclure, M., Sherwood, J. B. & Muller, J. E. Triggering myocardial infarction by marijuana. Circulation 103, 2805–2809 (2001).

  111. 111.

    Weinstein, A., Livny, A. & Weizman, A. Brain imaging studies on the cognitive, pharmacological and neurobiological effects of cannabis in humans: evidence from studies of adult users. Curr. Pharm. Des. 22, 6366–6379 (2017).

  112. 112.

    Fitzcharles, M.-A., McDougall, J., Ste-Marie, P. A. & Padjen, I. Clinical implications for cannabinoid use in the rheumatic diseases: potential for help or harm? Arthritis Rheum. 64, 2417–2425 (2012).

  113. 113.

    Wilens, T. E., Biederman, J. & Spencer, T. J. Case study: adverse effects of smoking marijuana while receiving tricyclic antidepressants. J. Am. Acad. Child Adolesc. Psychiatry 36, 45–48 (1997).

  114. 114.

    Stoll, A. L., Cole, J. O. & Lukas, S. E. A case of mania as a result of fluoxetine-marijuana interaction. J. Clin. Psychiatry 52, 280–281 (1991).

  115. 115.

    Kokalj, A., Rijavec, N. & Tavčar, R. Delirium with anticholinergic symptoms after a combination of paliperidone and olanzapine pamoate in a patient known to smoke cannabis: an unfortunate coincidence. BMJ Case Rep. 2016, bcr2016214806 (2016).

  116. 116.

    Galiegue, S. et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232, 54–61 (1995).

  117. 117.

    Derocq, J.-M., Ségui, M., Marchand, J., Le Fur, G. & Casellas, P. Cannabinoids enhance human B cell growth at low nanomolar concentrations. FEBS Lett. 369, 177–182 (1995).

  118. 118.

    Schwarz, H., Blanco, F. J. & Lotz, M. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J. Neuroimmunol. 55, 107–115 (1994).

  119. 119.

    Chen, Y. & Buck, J. Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. J. Pharmacol. Exp. Ther. 293, 807–812 (2000).

  120. 120.

    El-Gohary, M. & Eid, M. A. Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students. Hum. Exp. Toxicol. 23, 149–156 (2004).

  121. 121.

    Wu, H.-Y. Y. et al. Cannabidiol-induced apoptosis in primary lymphocytes is associated with oxidative stress-dependent activation of caspase-8. Toxicol. Appl. Pharmacol. 226, 260–270 (2008).

  122. 122.

    Jan, T.-R., Su, S.-T., Wu, H.-Y. & Liao, M.-H. Suppressive effects of cannabidiol on antigen-specific antibody production and functional activity of splenocytes in ovalbumin-sensitized BALB/c mice. Int. Immunopharmacol. 7, 773–780 (2007).

  123. 123.

    Cencioni, M. T. et al. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS ONE 5, e8688 (2010).

  124. 124.

    Rieder, S. A., Chauhan, A., Singh, U., Nagarkatti, M. & Nagarkatti, P. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology 215, 598–605 (2010).

  125. 125.

    Abo-Elnazar, S., Moaaz, M., Ghoneim, H., Molokhia, T. & El-Korany, W. Th17/Treg imbalance in opioids and cannabinoids addiction: relationship to NF-κB activation in CD4 + T cells. Egypt. J. Immunol. 21, 43–47 (2014).

  126. 126.

    Maresz, K. et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat. Med. 13, 492–497 (2007).

  127. 127.

    Parker, J. et al. Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid. Rheumatol. Int. 28, 631–635 (2008).

  128. 128.

    Chang, Y. H., Lee, S. T. & Lin, W. W. Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J. Cell. Biochem. 81, 715–723 (2001).

  129. 129.

    Correa, F., Mestre, L., Docagne, F. & Guaza, C. Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br. J. Pharmacol. 145, 441–448 (2005).

  130. 130.

    Selvi, E. et al. Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes. Clin. Exp. Rheumatol. 26, 574–581 (2008).

  131. 131.

    Johnson, D. R., Stebulis, J. A., Rossetti, R. G., Burstein, S. H. & Zurier, R. B. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. J. Cell. Biochem. 100, 184–190 (2007).

Download references


The authors thank E. Israeli for his comments on the manuscript.

Author information


  1. Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel

    • Daphna Katz-Talmor
    • , Itay Katz
    • , Bat-Sheva Porat-Katz
    •  & Yehuda Shoenfeld
  2. Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

    • Daphna Katz-Talmor
  3. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    • Itay Katz
    •  & Yehuda Shoenfeld
  4. Robert H. Smith Faculty of Agriculture, Food and Environment, School of Nutritional Sciences, Hebrew University of Jerusalem, Rehovot, Israel

    • Bat-Sheva Porat-Katz


  1. Search for Daphna Katz-Talmor in:

  2. Search for Itay Katz in:

  3. Search for Bat-Sheva Porat-Katz in:

  4. Search for Yehuda Shoenfeld in:


Y.S., D.K.-T. and I.K. researched data for and wrote the article. D.K.-T. and Y.S. substantially contributed to discussion of content. All authors reviewed and edited the manuscript before submission.

Competing interests

The authors declare no competing interests.

Corresponding author

Correspondence to Yehuda Shoenfeld.

About this article

Publication history